Anil Ananthaneni, MD

Hematology/Oncology Fellow @LSUHS | Former Internal Medicine Residency @LSUHS | Former Internship and Clinical Research Coordinator @StJohns_Blr

[Anil Ananthaneni, MD @Ananth_MD]

@RohitBanwar Interestingly, BR.31 (durvalumab) also had negative results. I believe mandating a pre-randomization PET, a 10 week delay after post op/post chemo, better nodal clearance and insufficient “critical mass” after R0 for immune priming might have picked patients with the lowest risk

[Anil Ananthaneni, MD @Ananth_MD]

Diagnostic stewardship is essential in high-stakes hematology. Reconsidering how we utilize ADAMTS13 testing for aTTP can improve diagnostic accuracy and resource allocation. Read our article published on @AjmQonline

https://t.co/oZYvNL2QKc

[Anil Ananthaneni, MD @Ananth_MD]

@HadidiSamer @umariqbalmed @JAMA_current A very refreshing read, and I agree with the points raised throughout. The trend of poor abstract-to-manuscript follow-through should be discouraged in academia.

[Samer Al Hadidi, MD,MS,FACP @HadidiSamer]

Check our viewpoint published @JAMA_current #MedEd

Abstract Factory—Research Culture Harming Medical Education

The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.

➡️https://t.co/IMBhy45L1K

@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG

[Anil Ananthaneni, MD @Ananth_MD]

Last day at #ASH25. Excited to share that our work was selected for an Abstract Achievement Award at this year’s ASH meeting in Orlando, FL! @ASH_hematology

[Anil Ananthaneni, MD @Ananth_MD]

@SrinishantR @AjuVaniBabu Congrats! Just a friendly reminder that the abstracts including titles are embargoed until 11/03

[Keith Siau @drkeithsiau]

Radiation doses of common radiological procedures #4KMedEd 🩻 ☢️

Transatlantic flight: 0.2mSv
Average background radiation: 3mSv/yr

[Toni Choueiri, MD @DrChoueiri]

JUST IN: @US_FDA approves imlunestrant (Inluriyo, @EliLillyandCo), an ER antagonist, for adults with ER (+), HER-2 (-), ESR1-mutated metastatic breast cancer with 1+ prior endocrine therapy. Approval based on EMBER-3 published in @NEJM with 1st author @jhaveri_komal @MSKCancerCenter

https://t.co/QDBuKcttGb

[Eric Rios-Doria, MD @RiosDoriaMD]

🚨Have you heard about the latest @US_FDA approval?

✅ #Pembrolizumab has been approved for subcutaneous administration

✅ This may offer greater convenience for patients receiving this drug, including those with #gyncancer like #EndometrialCancer and #CervicalCancer

➡️ More info: https://t.co/0DhFLHfzpP

❓ What are your thoughts about this new approval? @leitaomd @karenluMD @LAMcAlarnenMD @JCohenMD @pedroramirezMD @GynCancerMD @amandanfader @BillzamMD @RyanKahnMD1 @GreggNelsonERAS @ShannonWestin @gyncsm #gyncsm #oncology @OncBrothers @PGrivasMDPhD @CParkMD #gcam @KEYTRUDA

[Yakup Ergün @dr_yakupergun]

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

@FordePatrick et al.

https://t.co/fK56u2FrB4

[Anil Ananthaneni, MD @Ananth_MD]

Postoperative radiotherapy and survival outcomes in pN2 non-small-cell lung cancer with positive surgical margins: An updated review of the National Cancer Database #ASCO
https://t.co/fxAjYmtJ3x

[Anil Ananthaneni, MD @Ananth_MD]

A pleasant surprise in the mail today and honored to be recognized as a top reviewer for JCO Oncology Practice! As an author, I know how much a timely/quality peer review matters. Grateful to contribute to the process! Thank you @ASCO @JCOOP_ASCO

[Anil Ananthaneni, MD @Ananth_MD]

TMA in adult onset Still’s disease is a very rare entity with poor outcomes (>50% permanent complication rate). Unknown if this occurs by chance or association. Please read our report on this topic!
#AOSD #TMA #TTP #Still’s

https://t.co/I5GcnnJGHs

[Talha Badar @TalhaBadarMD]

#Weekend_review #TP53 #AML #COMMAND_Consortium

1/ I will share our collaborative effort in looking at different aspects of TP53 mutated AML: 🧵

(1) impact of induction strategy on outcome 10.1002/ajh.26546

(2) Transplant outcome 10.1038/s41375-023-01847-7

(3) Racial disparities in treatment and outcomes 10.1002/cncr.34604

(4) Impact of venetoclax addition to HMA on response and survival 10.1038/s41408-024-01000-2

(5) Impact of “single” vs “multi-hit” TP53 10.3324/haematol.2024.285000

I can not thank enough to all the collaborators of #COMMAND_consortium 🙏🙏🙏

[Anil Ananthaneni, MD @Ananth_MD]

@UGrewalMD @LSUHS @LSUHSResearch Thank you Udhay! The peer reviews and revisions took more than a year but we are really glad it’s finally out with open access, fully sponsored by @abhhoficial

[Anil Ananthaneni, MD @Ananth_MD]

Scheduled partial exchange transfusions were a/w decreased hospital admissions and increased gestational age at delivery in pregnant women with severe sickle cell disease. No significant differences in other natal outcomes including alloimmunization —>

https://t.co/vmf690Bn4s

[Anil Ananthaneni, MD @Ananth_MD]

Our results are similar to the TAPS2 RCT feasibility/acceptability study results published recently —> https://t.co/ni7g43XuCk

[Anil Ananthaneni, MD @Ananth_MD]

Grateful to the JCO Oncology Practice editorial team and Dr. Burton for the opportunity to discuss the crucial topic of oncofertility. Read our editorial: https://t.co/wzKYwPPZDZ @JCOOP_ASCO #Oncofertility #CancerCare #FertilityPreservation

[ASCO @ASCO]

Practice-changing news from #GU24: KEYNOTE-564 data support adjuvant pembro as a standard of care after surgery for patients with ccRCC at higher risk for recurrence: https://t.co/5ZzE3pHyy9 #ASCODailyNews @DrChoueiri @PBarataMD

[Anil Ananthaneni, MD @Ananth_MD]

Are We Diagnosing and Managing Diabetes in Patients with Sickle Cell Disorders Accurately?

https://t.co/wavhLv7W8A